Abstract: Previous studies showed that Gynura procumbens reduced blood pressure by blocking calcium channels and inhibiting the angiotensin-converting enzyme activity. The present experiments were to further explore the effects and mechanisms of a purer aqueous fraction (FA-I) of G. procumbens on angiotensin I (Ang I)-induced and angiotensin II (Ang II)-induced contraction of aortic rings and also on the bradykinin (BK) effect on cardiovascular system. Rat aortic rings suspended in organ chambers were used to investigate the vascular reactivity of FA-I. Effect of FA-I on BK was studied by in vitro and in vivo methods. Results show that FA-I significantly (P , 0.05) decreased the contraction evoked by Ang I and Ang II. In the presence of indomethacin (10 mM) or N v -nitro-L-arginine methyl ester (0.1 mM), the inhibitory effect of FA-I on Ang II-induced contraction of aortic rings was reduced. Besides, FA-I potentiated the vasorelaxant effect and enhanced the blood pressure-lowering effect of BK. In conclusion, FA-I reduced the contraction evoked by Ang II probably via the endothelium-dependent pathways, which involve activation of the release of nitric oxide and prostaglandins. The inhibition of angiotensin-converting enzyme activity by FA-I may contribute to the potentiation of the effects of BK on cardiovascular system.
INTRODUCTION
Normal blood pressure (BP) is partly maintained by the renin-angiotensin system (RAS) that regulates total sodium content and hence extracellular fluid volume. 1 One of the key enzymes in the RAS is angiotensin-converting enzyme (ACE). The pathway in which ACE splits 2 amino acids from the inactive decapeptide, angiotensin I (Ang I), to the octapeptide, angiotensin II (Ang II), that causes vasocontraction, aldosterone release, sodium and water retention, 1 and increasing oxidative stress 2 is well-known. However, less studied is that ACE also metabolizes bradykinin (BK), a vasodilator produced in the kinin-kallikrein system. 3 Consequently, inhibition of ACE decreases both the formation of Ang II and hydrolysis of BK that subsequently brings about increased diuresis and a fall in BP. 4 Therefore, inhibition of ACE is considered to be an effective therapeutic approach in treating hypertension. Most of the clinically used ACE inhibitors such as captopril, enalapril, and ramipril are effective not only in reducing BP but also in conferring beneficial effects on the cardiovascular system that seem to act mainly through the RAS. [5] [6] [7] Moreover, most of the said ACE inhibitors are with side effects that range from mild to serious. 8 Thus, exploration for new alternatives particularly in the plant kingdom as replacements for these drugs may provide invaluable findings.
Gynura procumbens Merr. (Compositae), a fast growing herbaceous plant, is used frequently in folk medicine for treating kidney diseases, fever, and rashes 9 and for hypertension. Previous studies from our laboratory have shown that extracts from this plant are able to reduce BP by blocking calcium channels 10 and inhibiting ACE activity, 11 besides being capable of lowering plasma lipids 12 and inhibiting renal mesangial cell proliferation. 13 However, these studies were performed using relatively less purified extracts. Moreover, in view of the fact that Ang II increases BP mainly by vasocontraction and ACE is involved in the degradation of BK, this study is thus initiated to explore further the effects and mechanisms of action of a purer aqueous fraction (FA-I) of G. procumbens on vasoreactivity and BP.
MATERIALS AND METHODS
All studies on experimental animals have been conducted under protocols reviewed and approved by the Animal Ethics Committee, University of Malaya Medical Centre.
Plant Materials
Whole plants of G. procumbens, excluding the roots, were collected from Peninsular Malaysia with a voucher specimen (KLU 047690) being deposited in the Herbarium at "Rimba Ilmu," University of Malaya.
Extraction and Fractionation of Plant Material
Leaves from fresh plants were cleaned and dried in an oven at 40 o C and then ground to powder. A crude ethanolic extract was obtained by macerating the powder with 96% ethanol at room temperature for 72 hours. After that, the extract was concentrated to dryness in vacuo, and this resulted in a gummy dark residue that was then reconstituted in 80% aqueous ethanol. The resulting solution was partitioned with hexane in a separating funnel. The lower aqueous ethanolic layer was collected and subjected to evaporation in vacuo to remove the ethanol but leaving behind an aqueous solution that contained an ethanolsoluble precipitate that was subsequently filtered out. The precipitate-free aqueous solution was then further partitioned against water-saturated n-butanol. The aqueous phase from this partition was collected and lyophilized to obtain the final aqueous fraction, which was further purified by passing it through a column containing Sephadex LH-20 gel using water as the eluent resulting in a much purer fraction, the FA-I fraction.
Animals
Adult male albino Sprague-Dawley rats, weighing between 250 and 320 g, were obtained from the Experimental Animal Care Unit, University of Malaya, and kept under standard conditions. Normal commercial rat chow (Gold Coin Animal Feed, Klang, Malaysia) and tap water were provided ad libitum.
In Vitro Experiments: Studies on Isolated Rat Thoracic Aortic Rings Preparation of Rat Aortic Rings
The rats were sacrificed by decapitation, and the descending thoracic aorta was rapidly isolated and placed in a petri dish containing ice-cold oxygenated Krebs-Henseleit solution of the following composition (in mM): NaCl, 118.0; KCl, 4.7; CaCl 2 , 1.25; MgSO 4 , 1.2; KH 2 PO 4 , 1.2; NaHCO 3 , 24.9; and glucose, 11.1. The aorta was cleaned of connective and adipose tissues and then cut into rings of 1-3 mm in length. Each aortic ring was mounted in an organ bath containing 10 mL Krebs-Henseleit solution with 2 stainless steel hooks as follows: the lower hook was fixed to the bottom of the bath, whereas the upper hook was connected to a force-displacement transducer to measure changes in the isometric contractile force that were recorded by a computerized physiograph system (PowerLab computer system; AD Instruments Pty. Ltd., Bella Vista, Australia). The bath solutions were maintained at a temperature of 37 o C and bubbled continuously with 95% oxygen and 5% carbon dioxide gas mixture. The aortic rings were subjected to a resting tension of 1 g and allowed to equilibrate for 60 minutes although being rinsed every 15 minutes. Before each experiment, the aortic rings were stimulated at least 3 times with 6 · 10 -2 M KCl until reproducible contractile responses were obtained.
Endothelium-denuded rings were prepared by inserting a pair of fine forceps into the lumen and gently rotating the rings around the forceps. These endothelium-denuded rings were similarly equilibrated in the organ baths for 60 minutes. The success of endothelial denudation was tested by precontracting the rings with phenylephrine (PE; 1 · 10 26 M) and observing the response to acetylcholine (1 · 10 25 M). A lack of any relaxation of the PE-precontracted rings indicated that the endothelium was satisfactorily removed, whereas relaxation of at least 70% of the PE-induced contraction showed that the endothelial layer was still present.
Effects of FA-I Pretreatment on Ang I-Induced Contraction
Endothelium-intact and endothelium-denuded aortic rings were preincubated for 20 minutes in the absence or presence of FA-I (1.0 · 10 24 and 1.0 · 10 23 g/mL). After the incubation period, contraction of the rings was evoked by adding cumulative 
Effects of FA-I Pretreatment on Ang II-Induced Contraction of Aortic Rings in the Presence of N v -nitro-L-arginine Methyl Ester or Indomethacin
To study the involvement of endothelium in response to Ang II brought by FA-I, endothelium-intact rings were preincubated with or without FA-I and indomethacin (10 mM), a nonselective cyclooxygenase (COX) inhibitor, or N v -nitro-L-arginine methyl ester (L-NAME; 0.1 mM), an endothelial nitric oxide synthase (eNOS) inhibitor, and followed by the cumulative additions of Ang II.
Effects of FA-I Pretreatment on BK-Induced Relaxation of PE-Precontracted Aortic Rings
After the equilibration period, the aortic rings were precontracted again with PE (1 · 10 26 M). The contractions of aortic rings to PE were allowed to reach a plateau before the cumulative additions of BK (1 · 10 211 M to 1 · 10 26 M). The relaxation responses of PE-precontracted aortic rings to the cumulative additions of BK were determined in the presence or absence of pretreatment with FA-I (1.0 · 10 24 and 1.0 · 10 23 g/mL) 20 minutes before the subsequent sequential additions of PE and BK.
In Vivo Experiments: Effects of FA-I on the Action of BK on Mean Arterial Pressure and Heart Rate of Rats Rats were anaesthetized with sodium pentobarbitone (60%, wt/vol), 50 mg/kg, by intraperitoneal injections. Each rat was placed on a surgical board, and the right jugular vein, left carotid artery, and trachea were surgically exposed. Heparinized polyethylene tubing was inserted into the carotid artery for continuous monitoring of the BP via a pressure transducer connected to the PowerLab computer system. The jugular vein was cannulated with a heparinized polyethylene tubing for intravenous injections of the test solutions, whereas the trachea was cannulated to facilitate spontaneous respiration. Small animal electrographic leads were attached to the limbs of the animal to monitor the heart rate (HR), with the running electrocardiogram being recorded from lead II. The animal was kept warm (35 6 2ºC) with a heating lamp throughout the experiment. The setup was allowed to equilibrate for at least 30 minutes before the commencement of the experiments.
After the equilibration period, intravenous injections of BK at different doses (0-625 ng/kg) were done before and after FA-I (10 mg/kg) administration. A minimum interval of 3 minutes was allowed between each injection. Changes in the BP due to the administration of BK and FA-I were obtained by calculating the difference between the BP before and the lowest BP after the injections. The mean arterial pressure (MAP) was calculated by using the following formula: MAP = DBP + 1/3(SBP 2 DBP), where DBP is diastolic BP and SBP being systolic BP.
Chemicals and Drugs
All drugs and chemicals were obtained from Sigma Chemical Co. (St Louis, MO) except heparin (Leo Pharmaceutical Products; Ballerup, Denmark) and BK and Ang I (human) (Merck KGaA; Darmstadt, Germany). All chemicals and solvents were of analytical grade.
Data Analysis
When the cumulative concentration-response curves with Ang I and Ang II were compared, the contractions in the presence of FA-I were calculated as a percentage of the highest contractile response obtained in the absence of FA-I. This contractile response evoked by the highest concentration of Ang I or Ang II was designated as E max . The pEC 50 value (-log EC 50 ) determined from the EC 50 value, which is the concentration required to produce a half-effect in the concentration-response curves, was calculated from individual log concentrationresponse curves of the Ang I or Ang II by sigmoidal nonlinear regression analysis within the 95% confidence intervals using GraphPad Prism v.4.00 (GraphPad Software Inc., La Jolla, CA). The vasorelaxant response to BK was measured from the plateau of the PE-induced contraction and expressed as a percentage relaxation of the PE-induced contraction.
Statistical Analysis
All values are expressed as mean 6 SEM for n number of rats or separate experiments. Statistical differences were evaluated by Student's t test. A probability level of less than 0.05 (P , 0.05) was considered to be significantly different.
RESULTS

In Vitro Experiments: Studies on Isolated Rat Thoracic Aortic Rings Effects of FA-I Pretreatment on Ang I-Induced Contraction
Pretreatment with FA-I at 1.0 · 10 24 and 1.0 · 10 23 g/mL inhibited the Ang I-induced contraction of both endotheliumintact (Fig. 1A) and endothelium-denuded (Fig. 1B) aortic rings in a concentration-dependent manner with significant (P , 0.01) reduction in the E max values. Furthermore, rings that were kept intact relaxed significantly (P , 0.05) more than those that were denuded of endothelium.
Effects of FA-I Pretreatment on Ang II-Induced Contraction
Experiments were then carried out with endotheliumintact and endothelium-denuded aortic rings to study the involvement of endothelium in the response of FA-I to the contraction evoked by Ang II. Results show that pretreatment of endothelium-intact aortic rings with FA-I attenuated the contraction caused by Ang II (Fig. 2A) , with the E max values being significantly (P , 0.001) decreased when compared with controls. However, exposure of endothelium-denuded aortic rings to FA-I for 20 minutes before the addition of increasing concentrations of Ang II did not blunt the contractions induced by Ang II (Fig. 2B) .
Effects of FA-I Pretreatment on Ang II-Induced Contraction of Aortic Rings in the Presence of L-NAME or Indomethacin
To further study the role of endothelial factors in the action of FA-I, Ang II-induced contraction in endotheliumintact rings were performed in the presence of both FA-I and L-NAME or indomethacin. Results show that pretreatment of FA-I at 1.0 · 10 24 and 1.0 · 10 23 g/mL in the presence of L-NAME (Fig. 3A) or indomethacin (Fig. 3B) did not cause any significant changes in the E max values for Ang II as compared with controls.
In aortic rings pretreated with L-NAME, although there were no significant changes in E max values, the concentration-response curves of Ang II are shifted to the right (Fig.  3A) with a significant (P , 0.05) decrease in pEC 50 values (Table 1) . Similarly, preincubation of FA-I and indomethacin also shifted the concentration-response curve to the right (Fig. 3B) , with a significant (P , 0.01) reduction of pEC 50 values for Ang II in the presence of FA-I at 1.0 · 10 23 g/mL (Table 1) . These results show that the eNOS and COX pathways may be involved in the response of FA-I on Ang IIinduced contraction of aortic rings. Figure 4 shows the comparison of the E max values obtained for Ang II-induced contraction of aortic rings preincubated with FA-I in the presence or absence of L-NAME or indomethacin. Preincubation of aortic rings with FA-I and L-NAME produced a significantly (P , 0.05) higher E max value than the controls (FA-I and Ang II). For preincubation of aortic rings with FA-I and indomethacin, only the higher concentration of FA-I, which is 1.0 · 10 23 g/mL possesses significant (P , 0.05) higher E max value than the controls. In addition, at the lower dose, the abolishment of the vasodilatory effect due to FA-I by L-NAME is more significant (P , 0.05) than that observed for indomethacin.
Effects of FA-I Pretreatment on BK-Induced Relaxation of PE-Precontracted Aortic Rings
Bradykin (BK) (1 · 10 211 to 1 · 10 26 M) dose-dependently relaxed PE-induced contraction of aortic rings. This observation was significantly (P , 0.05) enhanced by pretreatment of aortic rings with FA-I (Fig. 5) .
In Vivo Experiments: Effects of FA-I on the Action of BK on MAP and HR of Rats
Intravenous administrations of BK at different doses induced immediate and significant (P , 0.05) decrease in the MAP (Fig. 6A) and HR (Fig. 6B ) of rats. After pretreatment with 10 mg/kg FA-I, the BP-lowering effect produced by BK was markedly (P , 0.05) greater. The effect of lowest concentration of BK, 39 ng/kg (26.7 6 1.5 mmHg) after FA-I administration was more pronounced than the effect produced by highest concentration of BK, 625 ng/kg (25.1 6 1.3 mmHg) before FA-I administration. The difference in the hypotensive effect of BK before and after FA-I pretreatment became significant (P , 0.05) at doses of 78, 156, 312, and 625 ng/kg. BK also decreased the HR, but there was no significant difference in the bradycardic effect between before and after FA-I administration. Predose baseline levels were recovered within 10 minutes after BK administration.
DISCUSSION
This study confirms and extends previous work that clearly demonstrated the BP-lowering effects of the plant, G. procumbens, by inhibition of ACE activity. 11 Furthermore, the results of this investigation also provide convincing evidence for a novel vascular response of FA-I, that is, it is able to antagonize the vasoconstrictive effect of Ang II.
As shown in Figure 1 , preincubation with FA-I significantly inhibited the Ang I-induced vasocontraction in both endothelium-intact and endothelium-denuded aortic rings, with the degree of relaxation produced in endothelium-intact rings being significantly (P , 0.05) greater than that obtained in the denuded ones. These observations indicate that the actions of FA-I are more enhanced in the presence of the endothelium, probably because of the presence of nitric oxide (NO) 14 and prostacyclin (PGI 2 ). 15 The effects are likely to be mediated through the newly converted Ang II from Ang I by ACE that are abundantly found in aortic rings 16, 17 as Ang I per se seems to have no physiological function. 18, 19 Angiotensin II is a potent vasocontractor and acts mainly through the widely distributed Ang II type 1 receptor (AT 1 R) to increase BP. 1 Increased RAS activity, which leads to the increase in Ang II, has been implicated as a major contributing factor in the development of hypertension. 20 The present study shows a novel finding that FA-I is able to inhibit the Ang II-induced contraction of aortic rings with endothelium ( Fig. 2A ). Experiments were then carried out on endothelium-denuded aortic rings to investigate the involvement of endothelium on the effect of FA-I on Ang II-induced contraction of aortic rings. In endotheliumdenuded aortic rings, FA-I did not seem to have a significant effect on the contraction evoked by Ang II (Fig. 2B ). This may therefore exclude the notion that FA-I could be an AT 1 R blocker as AT 1 R blockers are known to inhibit Ang II-induced contractions in endothelium-denuded aortic rings as well. 21, 22 Hence, this strongly suggests that the inhibitory effect of FA-I on the vascular contraction is entirely endothelium dependent.
It is well known that the endothelium plays an important role in the regulation of vascular tone by releasing both relaxant and contractile factors in response to chemical and physical stimulation. 14, 15, 23 The vasorelaxant substances released by endothelial cells include NO mainly produced by eNOS, 14 PGI 2 produced by the COX pathway, 15 and endothelium-derived hyperpolarizing factor. 23 In the present study, the inhibitory effect of FA-I on the Ang II-induced contraction of aortic rings was diminished in the presence of L-NAME (Fig. 3A) or indomethacin (Fig. 3B) , with significant (P , 0.01) reduction in pEC 50 values (Table 1 ) but no significant difference in E max values. These novel findings support the notion that FA-I is able to counteract the contractile response of Ang II by stimulating the release of vasorelaxing factors via both the eNOS and COX pathways. Furthermore, in the presence of L-NAME in which eNOS is inhibited, FA-I is able to prevent the Ang II-induced contraction by triggering the release of PGI 2 (Fig. 3A) . Similarly, in the presence of indomethacin, FA-I is able to stimulate the release of NO, despite COX being inhibited (Fig. 3B) . In addition, preincubation of aortic rings with L-NAME caused a greater loss of the vasorelaxant response of FA-I than that of aortic rings preincubated 
FIGURE 4.
Comparison of the highest E max values for respective FA-I on angiotensin II-induced contraction in aortic rings preincubated with or without L-NAME or indomethacin. The effect was determined in the absence or presence of L-NAME or indomethacin. Values are mean 6 SEM (control, n = 7; others, n = 6). NS, not significant; *P , 0.05; **P , 0.01 compared with controls. with indomethacin (Fig. 4) . These findings clearly indicate and support the data from Figure 2 that FA-I attenuates the Ang II-induced vasocontraction mainly through the endothelium-dependent pathway with NO rather than PGI 2 playing a major role. Apart from the effect of FA-I on Ang I-induced and Ang II-induced contractions, effect of FA-I on the relaxation response to BK was also studied (Fig. 5) . BK is a vasodilator produced in the kinin-kallikrein system 3 wherein 2 types of receptors have been defined as follows: B 1 and B 2 receptors with most of the effects of BK being mediated by B 2 receptor under normal conditions. 5 Inhibition of ACE may partly potentiate the actions of BK, by either an indirect action on B 2 receptor or direct activation of B 1 receptor, [24] [25] [26] [27] and thus confer additional benefits to the cardiovascular system. Studies shown here demonstrated that FA-I does indeed enhance the vasorelaxant (in vitro study) and BP-lowering (in vivo study) effects of BK. The concentration of FA-I (10 mg/kg) used has no effect on the PE-induced contraction of aortic rings before cumulative addition of BK, as there was no significant difference in the magnitude of the PE-induced contraction in the presence or absence of FA-I (data not shown). In the study on aortic rings, FA-I enhanced the relaxation effect brought about by BK on PE-precontracted endothelium-intact aortic rings (Fig. 5) . However, parallel experiments on endothelium-denuded rings were not performed as it is well established that vasodilation caused by BK is entirely endothelium dependent. 28, 29 In the in vivo studies, the BP-lowering effect of BK was enhanced by FA-I (Fig. 6A) . Although BK is known to cause bradycardia, 30 the infusion of FA-I did not alter the bradycardic effect of BK (Fig. 6B ). This could be due to the baroreceptor reflex 31, 32 being involved in preventing further reduction in the HR brought about by FA-I. Hence, FA-I is able to potentiate the hypotensive effect of BK by enhancing the vasodilator activities through inhibition of ACE or by indirect action on the BK B 2 receptor, but without alteration in HR. Nevertheless, the exact mechanism responsible for the BK potentiation effect of FA-I remains to be elucidated.
CONCLUSIONS
This study conclusively demonstrates and extends previous investigations that FA-I, fractionated from the leaves of G. procumbens, has potent ACE-inhibiting activity. In addition, a novel finding of FA-I being able to antagonize the vasoconstrictive effect of Ang II is reported. The effect of FA-I on Ang II-induced contraction of aortic rings seems to be mediated by an endothelium-dependent pathway that involves the activation of NO and COX mechanisms. Furthermore, FA-I is able to enhance the BK effect, most probably by stimulation of the release of NO and PGI 2 . Therefore, FA-I could be developed into a more superior form of treatment for hypertension with dual effects than the conventional ones available now.
